Oppenheimer Asset Management Inc. Has $352,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Oppenheimer Asset Management Inc. trimmed its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLDFree Report) by 35.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,000 shares of the biopharmaceutical company’s stock after selling 18,352 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Amicus Therapeutics were worth $352,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Janus Henderson Group PLC increased its holdings in Amicus Therapeutics by 20.1% in the first quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after purchasing an additional 2,307,385 shares in the last quarter. William Blair Investment Management LLC increased its stake in shares of Amicus Therapeutics by 12.8% in the 2nd quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock valued at $128,993,000 after acquiring an additional 1,477,084 shares in the last quarter. Fiera Capital Corp lifted its position in shares of Amicus Therapeutics by 1.1% during the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in Amicus Therapeutics by 14.3% during the second quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock worth $29,964,000 after acquiring an additional 378,999 shares in the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Amicus Therapeutics by 17.9% in the second quarter. Victory Capital Management Inc. now owns 2,273,959 shares of the biopharmaceutical company’s stock worth $22,558,000 after purchasing an additional 345,117 shares during the period.

Insider Activity at Amicus Therapeutics

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 30,401 shares of company stock worth $352,038. 2.20% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on FOLD shares. StockNews.com raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday. Cantor Fitzgerald upped their target price on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Bank of America lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. Morgan Stanley lowered their price objective on Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research note on Friday, October 11th. Finally, Guggenheim lifted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.63.

Get Our Latest Research Report on Amicus Therapeutics

Amicus Therapeutics Stock Down 1.4 %

FOLD stock opened at $9.52 on Wednesday. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The stock has a market cap of $2.84 billion, a P/E ratio of -28.00 and a beta of 0.68. The stock’s fifty day simple moving average is $10.92 and its two-hundred day simple moving average is $10.60. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Amicus Therapeutics Profile

(Free Report)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.

Featured Stories

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLDFree Report).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.